Blatchford Ortopedi AS

Based in Norway, Blatchford Ortopedi AS specializes in advanced prosthetic and orthotic solutions designed to enhance mobility and improve quality of life for individuals with mobility challenges. Blatchford Ortopedi AS, headquartered in Kristiansand, Norway, focuses on the development and manufacturing of innovative prosthetic devices. Established in 2015, the company has a significant deal history, with its most recent transaction occurring on May 13, 2026, involving an Add-on funding round amounting to EUR 110. 000 mn from Ottobock SE & Co.

KGaA, enhancing its operational capabilities and market reach. The firm has completed 1 deal to date, reflecting its strategic initiatives in the healthcare sector. Blatchford specializes in the design and production of advanced prosthetic devices for lower extremities, including feet, knees, and limb systems, along with orthotic supports and custom insoles. Their core offerings feature Performance-Response Technology® prosthetics, engineered to enhance mobility, comfort, and overall quality of life for users facing significant mobility challenges.

Notable products include the Tectus® microprocessor-controlled orthosis for individuals with partial lower extremity paralysis, and SMARTSTEP®, a digital platform integrated into their prosthetics to provide healthcare professionals with data for optimizing treatment outcomes. Their clientele spans healthcare providers, rehabilitation centers, and end users across Europe and North America. Blatchford generates revenue through direct sales of its prosthetic and orthotic products to healthcare providers and end users, along with partnerships with rehabilitation facilities and clinics. The company's business model involves Business-to-Business (B2B) sales, equipping healthcare professionals with advanced tools for patient rehabilitation and mobility solutions.

Their premium products reflect advanced technology and bespoke tailoring, catering to clients who prioritize high-quality medical devices. The addition of services such as product support and customer service promotes long-term relationships with clients requiring ongoing assistance and product updates. Blatchford's recent acquisition by Ottobock SE & Co. KGaA positions the company to enhance its international patient care network and solidify its presence in the Norwegian healthcare market.

Future initiatives are expected to focus on expanding into new geographic regions and launching innovative products, leveraging the EUR 110. 000 mn funding secured in 2026 to facilitate these growth strategies.